Free tool
FAERS Monitor: Kapspargo Sprinkle
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210428 or its brand name (Kapspargo Sprinkle, Metoprolol Succinate). Reports on generic versions are filed under their own applications.
Reports
64,013
Serious
40,110
63% of reports
Hospitalization
21,660
Death reported
5,990
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue4,958
- diarrhoea4,077
- dyspnoea3,874
- nausea3,812
- dizziness3,238
- drug ineffective3,140
- off label use3,106
- headache2,969
- death2,656
- asthenia2,454
- pain2,317
- fall2,218
- cough2,081
- pneumonia1,971
- vomiting1,908
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 586 |
| 2005 | 535 |
| 2006 | 678 |
| 2007 | 1,507 |
| 2008 | 857 |
| 2009 | 1,212 |
| 2010 | 935 |
| 2011 | 1,611 |
| 2012 | 1,916 |
| 2013 | 567 |
| 2014 | 1,012 |
| 2015 | 1,828 |
| 2016 | 2,529 |
| 2017 | 3,265 |
| 2018 | 4,179 |
| 2019 | 4,262 |
| 2020 | 4,217 |
| 2021 | 3,973 |
| 2022 | 4,653 |
| 2023 | 5,082 |
| 2024 | 6,106 |
| 2025 | 7,085 |
| 2026 | 5,418 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,990,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| coughSignal | 2,081 | 2.4 | 2.3 | 1,793 |
| dyspnoeaSignal | 3,874 | 2.3 | 2.2 | 2,767 |
| fallSignal | 2,218 | 2.2 | 2.1 | 1,460 |
| astheniaSignal | 2,454 | 2.2 | 2.1 | 1,530 |
| dizzinessSignal | 3,238 | 2.1 | 2.1 | 2,001 |
| fatigueSignal | 4,958 | 2.1 | 2.0 | 2,944 |
| diarrhoeaSignal | 4,077 | 2.1 | 2.0 | 2,349 |
| pneumoniaSignal | 1,971 | 2.0 | 1.9 | 1,003 |
| nausea | 3,812 | 1.6 | 1.5 | 851 |
| headache | 2,969 | 1.6 | 1.5 | 609 |
| vomiting | 1,908 | 1.3 | 1.3 | 163 |
| pain | 2,317 | 1.2 | 1.2 | 110 |
| off label use | 3,106 | 1.2 | 1.1 | 76 |
| death | 2,656 | 1.0 | 1.0 | 0 |
| drug ineffective | 3,140 | 0.8 | 0.8 | 202 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.